Creative Innovation For Better Healthy Life

History

2016 10 Listed GL PharmTech on the KOSDAQ market
2015 12 Approved IND for Phase III Clinical study of the GLA5PR(pregabalin OAD)
  9 Won “K-BrainPower” award
  6 Approved IND for Phase I Clinical study of GLE1RCW
  2 Approved IND for Phase III Clinical study of the GLE3PA(paroxetine CR)
2014 12 Finished Phase I Clinical study(multiple administration) for GLA5PR(pregabalin OAD)
  5 Approved IND for Phase I Clinical study(dose-proportionality) of the GLA5PR(pregabalin OAD)
  4 Finished Phase I Clinical study(single administration) for GLA5PR(pregabalin OAD)
2013 12 G-SOREN® Tab. launched
    Approved IND for Phase III Clinical study of the GL2702(tamsulosin QD)
  10 Approved IND for Phase I Clinical study(multiple administration) of the GLA5PR(pregabalin OAD)
  8 Finished Phase I Clinical study for GL2907(oxycodone QD)
  4 Finished Phase I Clinical study(single administration) for GLA5PR(pregabalin OAD
2012 7 NDA Approval for G-SOREN® Tab.(Artemisiae Argyi Folium Isopropanol ext.)
    Approved IND for Phase I Clinical study(single administration) of the GLA5PR(pregabalin OAD)
    Approved IND for Phase I Clinical study(multiple administration) of the GLA5PR(pregabalin OAD)
  1 Approved IND for Phase I Clinical study(single administration) of the GL2907(oxycodone QD)
2011 11 Submitted IND for Phase I Clinical study of the GL2907(oxycodone QD)
  10 Completed Phase III Clinical study & NDA for GL2801(Artemisia asiatica ext. generic)
  9 Certification of 2011 'Best HRD(Human Resource Developer)'
    Finished Phase I Clinical study for GL2702(tamsulosin QD)
    Completed Phase III Clinical study for GL2701(tamsulosin plus finasteride complexes)
2010 10 Approved IND for Phase I Clinical study of the GL2702(tamsulosin QD)
  8 Approved IND for Phase III Clinical study of the new herbal extract for gastric ulcer medicine
  4 Fund of Small and Medium Business Administration for the new combination for BPH & OAB
medicine
2009 12 Received Certification authority of quality test (medical product) from Korea FDA
  10 Approved IND for Phase III Clinical study for the new combination for BPH medicine
  5 Licensing agreement of MUCRS technology with Siegfried Generics Int. Ltd.
  1 Fund of Seongnam city for Clinical study of the GL2701(new combination for BPH medicine)
2008 9 Patented GLARS
    Received Korea's first FDA certificate of approval for "Product-outsourced Marketing
Authorization" from Korea FDA
  6 Fund of Ministry for Food, Agriculture, Forestry and Fisheries for the feed additives containing the
enteric-coated enzyme
2007 12 NDA approval for the new salt of Sibutramine
  10 Licensing agreement for technical transfer of Pantoprazole tablets with YSP Malaysia
  7 Strategic alliance with Richwood Pharm. Co., Ltd.
  6 Fund of Small and Medium Business Administration for the commercialization of the new salt of
Sibutramine for anti-obesity
  5 Fund of Small and Medium Business Administration for the new CR formulation development for
antidepressants
2006 11 Certification of INNO-BIZ company from the Small and Medium Business Administration
2005 11 Won "Korea Patent-Driven Success 2005" award
  10 Won "Venture Korea 2005" award
  5 Fund of Ministry of Health and Welfare for the new formulation development for the
immunosuppressant
2003 1 Won "Korea Venture Business Model 2003" award
2002 8 Corporation founded